LYKALABSNSELyka Labs Limited· PharmaceuticalsLowNeutral
Announced Thu, 9 Apr · 19:54 IST

Ipca Laboratories Ltd. has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ownership Changes View source PDF

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹58.10
prior close
₹59.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1-2.7-0.2-0.5-0.3-2.1-0.7+3.2-0.1+2.4-1.0+10.2+23.9+23.5
Up moveDown movePending
AI summary

Ipca Laboratories Ltd. and the Godha family (promoters of Lyka Labs Limited) have submitted a declaration to NSE/BSE confirming that they have not created any encumbrance, directly or indirectly, on their equity shares in Lyka Labs Ltd. for the financial year ended 31 March 2026. The disclosure is made under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, which requires promoters to periodically declare their pledge position. This is a routine compliance filing and represents a negative declaration — meaning no pledge was placed on promoter shares during the period.

Likely market impact

A clean declaration with no encumbrances is a positive signal for investors as it indicates promoter confidence in the company and reduces risk of forced share sales. No immediate concern for shareholders.